INTRODUCTION
post-integration before CD4 is fully downregulated, would be most effective in limiting virus 79 production and spread. 80 81 While the possibility of time-dependent differential susceptibility to ADCC is a topic 82 that warrants investigation, it is important to note that in vitro measurements of anti-HIV-1 83 ADCC are complicated due to bystander effects that can confound data interpretation. 84
Indeed, HIV-1-infected cell cultures contain soluble gp120 that can bind to uninfected cells 85 and expose CD4i epitopes, allowing CD4i ADCC antibodies to bind and create ideal 86 bystander target cells for effector NK cells (13, 14) . It is plausible that a similar phenomenon 87 could result in early HIV-1-infected cells within in vitro cultures gaining ADCC epitopes 88 prior to de novo Env expression. As such, it is important to assess time-dependent anti-HIV-1 89 ADCC early following the infection of target cells to prevent the accumulation of shed 90 gp120. Another potential confounding variable for anti-HIV-1 ADCC measurements is the 91 viral inoculum, which contains both virions and gp120 that could stably bind to CD4 on the 92 surface of cells and reveal CD4i ADCC epitopes as well. In such a situation, the ADCC 93 epitopes would be available in exaggerated quantities to what would be available during the 94 infection of a cell by a single virion. Thus, caution needs to be taken in interpreting the 95 results of experiments assessing the time-dependence of anti-HIV-1 ADCC. 96 97 Herein we evaluate the temporal susceptibility of HIV-1-infected target cells to 98 ADCC, as well as the antibody specificity involved in the observed responses. Furthermore, 99
we assess if the detected responses were directed towards de novo Env, shed gp120 or 100 inoculum-derived Env that bound to cells during the infection process. We found that while 101 CD4 was not completely downregulated early in infection, there was limited or no de novo 102
Env expression at this stage. Our results suggest that inoculum-derived gp120 and virions are 103 
CD4 is progressively downregulated on HIV-1-infected cells 108
Several studies have shown that ADCC antibodies within sera and plasma from HIV-109 1-infected or vaccinated individuals predominantly target the CD4-bound conformation of 110 . A potential barrier for these antibodies to recognize HIV-1-infected cells is that 111
CD4i epitopes, exposed when Env binds to CD4, are concealed on infected cells due to the 112 downregulation of CD4 by Nef and Vpu (9) . To examine whether a window of opportunity 113 exists for CD4i antibodies to target HIV-1-infected cells before CD4 is fully downregulated, 114
we infected CEM cells with a GFP-reporter HIV-1 AD8 strain that expresses Nef (under the 115 control of an internal ribosome entry site (IRES)) and Vpu (15) . We examined CD4 and GFP 116 expression over time and show that CD4 is progressively downregulated as GFP increases 117 over a period of 12 to 48 hrs ( Fig 1A, top panel) . The cells transition from a CD4-high GFP -118 uninfected state to a CD4-intermediate state expressing low levels of GFP early in infection 119 (hereafter called CD4 int GFP lo ), and finally towards a CD4-low state expressing high levels of 120 GFP late in infection (hereafter called CD4 lo GFP hi ). The CD4 lo GFP hi cells become the 121 predominant population of GFP + infected cells over time ( Fig 1B) as CD4 is progressively 122 downregulated ( Fig 1C) . To examine the progression of infection in the absence of second 123 rounds of infection, we added the fusion inhibitor T20 4 hrs after spinoculation with HIV-124 1 AD8 . There was very little change in the percentage of cells transitioning to the CD4 int GFP lo 125 and CD4 lo GFP hi stages at each time point compared to cells without T20 ( Fig 1A, bottom  126 panel). Since T20 was added before a second round of infection could occur, we conclude 127 that the presence of CD4 int GFP lo cells at the 36-and 48-hr time points was likely due to a 128 delayed progression of infection from the initial viral inoculum. As a positive control, cells 129 treated with T20 prior to infection with HIV-1 AD8 mostly remained uninfected ( Fig 1A,  130 middle panel). 131 9 157 Polyclonal sera from HIV-1-infected individuals contain a large range of Env-specific 158 antibodies. To more finely dissect the Env epitopes expressed on infected cells, we examined 159 binding of several Env-specific mAbs ( Fig 2B) . The non-neutralizing A32 mAb, which binds 160 to a CD4i cluster A epitope on the inner domain of gp120 (11, 16) , predominantly recognized 161 the uninfected GFPbystanders that have gp120 bound to CD4 on the surface. A32 could 162 bind CD4 int GFP lo cells moderately well and even bound to CD4 lo GFP hi cells, showing that 163 either CD4 has not been fully downregulated on the CD4 lo GFP hi cells or that there may be 164 low levels of CD4i epitopes exposed on cells infected with HIV-1 AD8 even without CD4 165 ligation. The broadly neutralizing antibodies (bNAbs) 3BNC117 (CD4-binding site), PGT126 166 (N332 glycosylation site on V3 loop) and PGT145 (V1V2 apex) exhibited low levels of 167 binding to CD4 lo GFP hi infected cells, where Env is more likely to be in an unliganded 168 "closed" conformation. A mAb against influenza nucleoprotein (D1-11) served as an isotype 169 control for the staining of Env-specific mAbs (17). 170
171
We next assessed Env expression in primary CD4 + T cells infected with the GFP-172 reporter HIV-1 ADA strain (9) and stained with a similar panel of mAbs 48 hrs post-infection 173 ( Fig 3A) . A32-binding was dependent on the level of CD4, with the highest binding to 174 gp120-coated CD4 hi GFPuninfected bystander cells, moderate binding to CD4 int GFP lo cells 175 and low binding to CD4 lo GFP hi cells. The binding of 2G12, specific for a CD4-independent 176 outer domain epitope (18), showed that the uninfected bystanders had higher levels of gp120 177 compared to CD4 int GFP lo and CD4 lo GFP hi cells. In line with the results in Fig 2B, 
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Lastly, we examined the binding of mAbs and HIV-1 + sera antibodies to primary 181 CD4 + T cells infected with an HIV-1 infectious molecular clone expressing Env from a 182 transmitted/founder virus (CH077.t) 18 hrs post-infection using p24 expression as a readout 183 of infectivity ( Fig 3B) . The binding of HIV-1 + sera antibodies resembled the binding of A32, 184 with higher binding to CD4 int p24 + cells compared to CD4 lo p24 + cells. The bNAbs PGT126 185 and PGT151 (gp120-gp41 interface) predominantly recognized CD4 lo p24 + cells, with 186 moderate binding to CD4 int p24 + cells. 187
188
As a control, we also examined the binding of mAbs to cells infected with Nef-and 189
Vpu-deficient HIV-1. Without the antagonism of tetherin by Vpu and downregulation of CD4 190 by both Nef and Vpu, these infected cells have high levels of Env and CD4 on the surface, 191 resulting in high levels of binding of all antibodies tested (both CD4i and non-CD4i) (Fig 3A, 192 3B) . 193
194

CD4-intermediate infected cells are not more susceptible to ADCC compared to CD4-195 low infected cells 196
Having shown that HIV-1 + plasma and sera antibodies preferentially bind CD4 int 197 GFP lo over CD4 lo GFP hi cells, we next examined whether there was higher ADCC against 198 CD4 int GFP lo cells. Since uninfected GFPbystander cells have been shown to be good 199 targets for ADCC and could confound the measurement of ADCC responses (14), we first 200 sorted HIV-1 AD8 -infected CEM cells at 20 hrs post-infection into GFP -, GFP lo and GFP hi 201 cells to examine ADCC against the three populations independently. We found that the sorted 202 target cells, in the absence of effector NK cells or ADCC antibodies, continued to 203 downregulate CD4 and transition during the 5-hr ADCC assay incubation (Fig 4) CD4 lo GFP hi in the representative example shown. The sorted GFP hi cells remained CD4 lo but 207 continued to express HIV-1 (GFP) within the ADCC assay incubation, increasing in GFP 208 MFI from 14995 to 31999 after 5 hrs. This general pattern of continued CD4-downregulation 209 and GFP-expression post-sorting was observed across six independent experiments. 210
211
We examined ADCC against the sorted populations and calculated ADCC using a 212 reference population (eFluor670-stained uninfected CEM cells) that was "spiked" into each 213 sample at the end of the ADCC assay incubation ( Fig 5A) . We found that all three 214 populations were eliminated by ADCC in an HIV-1-specific manner compared to the HIV-1 -215 plasma control. Although there was higher binding of HIV-1 + plasma antibodies to CD4 int 216 GFP lo cells, there was no significant difference in %ADCC against the sorted GFP lo or GFP hi 217 cells (median 15.7% [interquartile range 12.3 to 31.1%] vs 20.5% [7.9 to 30.5%], p=0.87) 218 ( Fig 5C) . 219 220 As the sorted GFP lo cells (initially all CD4 int ) continued to downregulate CD4 during 221 the 5-hr ADCC assay incubation (Fig 4) , it was difficult to determine at which stage (CD4 int 222 or CD4 lo ) the cells were killed. Since a proportion of the apparently uninfected sorted GFP -223 cells at 20 hrs post-infection begin to express GFP over the 5-hr ADCC incubation (Fig 4) , 224
we could examine ADCC against this population to assess the killing of cells early during the 225 infection process. We therefore examined ADCC mediated by HIV-1 + plasma antibodies 226 against sorted GFPbystander cells that remain uninfected (GFP -) compared to the ~10% of 227 cells that become infected (GFP + ) during the 5-hr ADCC incubation. We found that there was 228 significantly higher ADCC against the cells that become GFP + compared to the cells that 229 remain GFP -(53.8% [32 to 83.3%] vs 27.7% [19 to 37.5%], p<0.0001) ( Fig 5B) . This 230 on March 18, 2019 by guest http://jvi.asm.org/ Downloaded from implies that early-stage infected cells could be better targets for ADCC compared to 231 uninfected bystander cells that have CD4-bound Env. 232 233 CD4-induced epitopes are important for ADCC against GFPcells and CD4-234
intermediate infected cells 235
Since A32-like antibodies against CD4i epitopes are common in HIV-1 + plasma (19), 236
we assessed whether A32 Fabs could block ADCC against HIV-1 AD8 -infected CEM cells. We 237 first show that A32 Fabs significantly reduced binding of HIV-1 + plasma IgG against CD4 hi 238 GFP -, CD4 int GFP lo and CD4 lo GFP hi cells ( Fig 6A) . Although binding of HIV-1 + plasma 239 antibodies to CD4 lo GFP hi cells was low, this binding could still be blocked with A32 Fabs, 240
suggesting that low levels of CD4i epitopes were still present on the CD4 lo GFP hi infected 241 cells. Next, we found that A32 Fabs significantly reduced ADCC against sorted GFPand 242 GFP lo cells ( Fig 6B) . Some HIV-1 + plasma donors still had relatively high ADCC even after 243 the A32 epitope was blocked, suggesting that these donors have ADCC antibodies that can 244 recognize other epitopes on Env. Lastly, we found that A32 Fabs did not significantly reduce 245 ADCC against sorted GFP hi cells. 246
247
ADCC against infected cells at an early stage is due to CD4-bound gp120 or virions that 248 originated from the viral inoculum 249
Shed gp120 in infected cell cultures can give rise to artefactual ADCC results if the 250 assay measures effector cell activation or killing of total target cells (i.e., uninfected 251 bystanders + infected cells) (14). Another source of Env that can bind to CD4 on uninfected 252 bystanders is the viral inoculum. To examine the possibility that sources of Env in the viral 253 inoculum were confounding our results, we examined ADCC against "HIV-1-exposed" CEM 254 cells in the presence of a CD4-blocking antibody or an isotype control. The "HIV-1-exposed" 255 on March 18, 2019 by guest http://jvi.asm.org/ Downloaded from 13 CEM cells were spinoculated with HIV-1 AD8 for 1 hr as for the above experiments, washed to 256 remove any unbound gp120 or virions and immediately used as targets for the ADCC assay 257 without any prior incubation for viral replication to occur. We observed that the "HIV-1-258 exposed" cells were significantly killed by ADCC compared to mock infected cells (isotype 259 control 15.7% [11.6 to 19.6%] vs mock 3.2% [1.8 to 5.9%], p<0.05) ( Fig 7A) , showing that 260 "HIV-1-exposed" cells can be targets for ADCC even without viral replication. The 261 sensitization of target cells to ADCC by the viral inoculum was CD4-dependent as blocking 262 CD4 prior to spinoculation significantly reduced ADCC (isotype control 15.7% [11.6% to 263 19.6%] vs CD4-blocked 2.6% [0.6-7.5%], p<0.05). Of note, spinoculation of CEM cells with 264 monomeric gp120, rather than viral preparations, also resulted in high levels of ADCC 265 mediated by HIV-1 + plasma (data not shown). We next stained "HIV-1-exposed" cells for 266 p24 expression to examine whether HIV-1 virions could be detected on the cell surface ( Fig  267   7D ). Immediately after spinoculation with HIV-1 AD8 , 68.3% of CD4 hi GFPuninfected cells 268 were p24 + compared to mock infected cells, reflecting HIV-1 virions attached to the surface 269 of the cells. As the CD4 hi GFPuninfected cells transitioned into CD4 int GFP lo cells, the 270 levels of p24 detected were similar to that of the CD4 hi GFPcells. In contrast, CD4 lo GFP hi 271 cells in the later stages of infection expressed p24 at levels exceeding CD4 hi GFPand CD4 int 272 GFP lo cells, most likely as the cells began to produce progeny virions. Thus, these results 273 suggest that a mix of gp120 and viral particles present in the inoculum is sufficient to 274 sensitize uninfected cells to ADCC. 275
276
We postulated that the A32-and HIV-1 + plasma IgG-binding detected against CD4 int 277 GFP lo early-infected cells (at 20 hrs post-infection) could have been due to gp120 or virions 278 from the viral inoculum instead of newly synthesized Env or gp120 shed from productively 279 infected cells. We therefore performed a time course and measured A32-and PGT126-280 on March 18, 2019 by guest http://jvi.asm.org/ Downloaded from binding from 12 to 48 hrs post-infection. A32-binding to uninfected GFPbystanders stayed 281 relatively stable (around 6.5 to 7 fold change in MFI over isotype control) from 12 to 24 hrs 282 post-infection ( Fig 7B) , likely reflecting binding to gp120 or virus particles that originated 283 from the viral inoculum. As for PGT126, the small increase in binding to CD4 lo GFP hi 284 infected cells from 18 to 48 hrs post-infection (1.2 to 1.6 fold over isotype) could reflect 285 binding to low levels of newly synthesized Env ( Fig 7C) . A32-binding to the GFP -286 bystanders increased greatly from 24 to 48 hrs (6.5 to 12.1 fold over isotype) whereas binding 287 to CD4 int and CD4 lo infected cells stayed relatively stable and did not increase over baseline 288 from 18 to 48 hrs ( Fig 7B) . The increasing amount of A32 bound on the surface of uninfected 289 bystander cells from 24 hrs onwards implies that the productively infected cells in culture 290
were only starting to shed gp120 after 24 hrs of incubation. In our in vitro infection model, we detected higher binding of HIV-1 + plasma 293 antibodies to CD4 int GFP lo early-stage infected cells compared to CD4 lo GFP hi late-stage 294 infected cells. This binding was mostly against CD4i epitopes as it was significantly blocked 295 by A32 Fabs, corroborating results from previous studies showing that HIV-1 + plasma 296 antibodies predominantly recognize the CD4-bound conformation of Env (6, 7). Our results 297
show that sorted GFP lo infected cells were not more susceptible to ADCC compared to sorted 298 GFP hi infected cells, though it was difficult to determine at which stage the sorted GFP lo cells 299 were killed (CD4 int or CD4 lo ) as they continued to downregulate CD4 and express GFP 300 during the ADCC assay incubation. Sorted GFPcells that become GFP + during the ADCC 301 assay were more susceptible to ADCC compared to the cells that remained GFP -, suggesting 302 that early-stage infected cells are better targets for ADCC than uninfected bystander cells 303 coated with gp120. 304
305
While it is plausible that CD4i antibodies can eliminate early-stage infected cells in 306 the process of CD4-downregulation, data from the antibody-binding time course experiments 307 suggest that these initial results could be tempered by the complicated nature of infecting 308 cells with HIV-1 in vitro. We observed that uninfected GFPbystander cells had similar 309 levels of A32-binding from 12 to 24 hrs post-infection, but increased two-fold from 24 to 48 310 hrs post-infection ( Fig 7B) . Since GFP expression was not detectable at 12 hrs post-infection 311 in that experiment, the A32-binding detected at 12 hrs was against CD4-bound gp120 or 312 virions that originated from the initial viral inoculum. That is, HIV-1 gp120-or virion-coated 313 uninfected bystander cells are not only generated during a culture of HIV-1 infection as 314 previously reported (13, 14) , but also through the simple addition of a viral inoculum. The 315 increase in A32-binding to GFPbystanders from 24 to 48 hrs implies that the productively 316 on March 18, 2019 by guest http://jvi.asm.org/ Downloaded from infected cells in culture (most likely GFP hi ) were shedding gp120 from 24 hrs onwards, 317 similar to previous observations (13). This led to an accumulation of shed gp120 and virions 318 attached to CD4 on uninfected bystander cells, thereby increasing the level of CD4i epitopes 319 available for A32-binding from 24 to 48 hrs. This time frame is in agreement with a previous 320 study showing that virus production begins approximately 24 hrs post-infection (20). Since 321 our earlier assays with HIV-1-infected CEM cells had been performed at 20 hrs post-322 infection, the CD4 int GFP lo early-stage infected cells most likely had CD4-bound gp120 or 323 virions that originated from the viral inoculum instead of newly synthesized Env. We 324 observed decreasing amounts of plasma IgG binding with decreasing levels of CD4 (CD4 hi 325 GFPbystanders > CD4 int GFP lo > CD4 lo GFP hi ) (Fig 2A) . If there was no newly synthesized 326
Env on the surface of the cells at 20 hrs post-infection, we speculate that the decreasing 327 amount of plasma IgG binding we observed in Fig 2A could be due to the downregulation of 328 CD4 along with bound gp120 or virions, instead of reduced levels of CD4 interacting with 329 newly synthesized Env. We also show that "HIV-1-exposed" cells (spinoculated with HIV-1 330 for 1 hr and washed without any further incubation) could be killed by ADCC prior to viral 331 replication ( Fig 7A) . These results were further corroborated by the detection of HIV-1 p24 332 on the surface of uninfected GFPbystander cells at 0 hrs post-infection, reflecting HIV-1 333 virions attached to the surface of these cells ( Fig 7D) . Therefore, similar to the uninfected 334 bystander cells, the plasma IgG binding and ADCC we detected against CD4 int GFP lo cells at 335 20 hrs post-infection was largely directed against CD4-bound gp120 or virions from the viral 336 inoculum. 337
338
These results bring into question whether CD4 int early infected cells are a real target 339 in vivo or an in vitro artefact due to the coating of cells with soluble gp120 and viral particles 340 from the inoculum. Previous studies have examined ADCC mediated by CD4i antibodies 341 on March 18, 2019 by guest http://jvi.asm.org/ Downloaded from against cells pulsed with inactivated virions, to mimic CD4i epitopes exposed upon binding 342 of viral Env to CD4 during HIV-1 entry (11, (21) (22) (23) . CD4i epitopes transiently revealed on 343 cells during HIV-1 entry (pre-integration) could present a narrow window of opportunity for 344
CD4i ADCC antibodies to block HIV-1 acquisition (12). However, the high levels of 345 inactivated virions used to pulse target cells in these studies are likely not reflective of HIV-1 346 transmission in vivo, which is usually characterized by the transmission of one founder viral 347 variant (24, 25) . Thus, we propose that the in vitro susceptibility of HIV-1 entry epitopes to 348 ADCC could largely be artefactual and would correspond to the level of virions used to pulse 349 target cells. As has been suggested for cytotoxic T lymphocytes (26) inoculum-derived gp120 and virions sensitizing target cells to ADCC prior to de novo Env 356 expression, the transfection of CD4 + target cells with HIV-1 DNA plasmids could be an 357 alternative approach to examine whether Env is expressed prior to complete CD4-358 downregulation and whether CD4 int Env-expressing cells are more susceptible to ADCC 359 mediated by HIV-1 + plasma antibodies compared to CD4 lo Env-expressing cells. 360 361 A potential caveat with using GFP-reporter viral constructs is that the GFP gene is 362 often in place of nef, with nef re-introduced downstream under the control of a wildtype 363 encephalomyocarditis virus (EMCV) IRES instead of the HIV-1 long terminal repeat (LTR) 364 promoter (15, 28) . A previous study reported that Nef could be over-expressed when under 365 the control of wildtype EMCV IRES compared to parental non-reporter viruses (28). As such, 366 on March 18, 2019 by guest http://jvi.asm.org/ Downloaded from CD4-downregulation due to IRES-driven Nef could progress faster than in cells infected with 367 wild-type HIV-1. We note however, that substantially similar antibody-staining results were 368 obtained with a primary infectious molecular clone (CH077.t) expressing physiological levels 369 of Nef (Fig 3B) , suggesting higher levels of Nef expression do not affect our conclusions. In 370 contrast, a recent study found that certain HIV-1 reporter viral constructs display suboptimal 371 expression of Nef in CD4 + T cells, resulting in poorer CD4-downregulation and a 372 corresponding increased exposure of CD4i ADCC epitopes (29). Thus, it is important to 373 consider Nef expression levels when selecting HIV-1 reporter viruses for usage in ADCC 374 assays to avoid a significant bias in ADCC mediated by CD4i antibodies. It should be noted 375 that in wildtype HIV-1 viruses, Nef is expressed early in the viral life cycle while Env and 376
Vpu are expressed later as they are dependent on an accumulation of Rev in the nucleus (30). 377
While Nef internalizes CD4 from the plasma membrane, Vpu targets newly synthesized CD4 378 at the endoplasmic reticulum, both pathways leading to the degradation of CD4 (31, 32). The 379 early expression of Nef and concomitant expression of Vpu along with Env ensures the 380 continuous removal of CD4 on HIV-1-infected cells, starting before Env expression at the 381 cell surface, thereby reducing the exposure of CD4i ADCC epitopes on Env. 382
383
In summary, we show in an in vitro experimental system that both CD4 int GFP lo early 384 and CD4 lo GFP hi late infected cells can be killed by HIV-1-specific ADCC, even though there 385 was significantly higher binding of HIV-1 + plasma antibodies to the CD4 int GFP lo cells. The 386 ADCC detected against these early infected cells, however, was largely artefactual due to the 387 high levels of soluble gp120 and virions from the initial viral inoculum binding to CD4, 388 sensitizing the early infected cells to ADCC prior to de novo Env expression. As such, future 389 studies examining ADCC against HIV-1 entry epitopes or early-stage infected cells should (15), followed by an 454 IRES-Nef coding sequence, was transiently transfected into HEK 293T cells using calcium 455 phosphate as previously described (35). Briefly, virus-containing supernatant was collected 456 after 2 days, filtered (0.45µm) and concentrated by ultracentrifugation through 20% sucrose. 457 Viral pellets were resuspended in a 75-fold smaller volume and aliquots were stored at -80ºC. 458
To normalize virus stocks, the 50% tissue culture infectious doses (TCID 50 ) were determined 459 by limiting dilution in TZM-bl cells using luciferase as a read-out for infection (Luciferase 460 Assay System, Promega). CEM cells were infected with GFP-reporter HIV-1 AD8 at an MOI 461 of 0.5 to 2 in 96-well plates by spinoculation at 1200g for 1 hr at 21ºC. Infected CEM cells 462 were then incubated at 37ºC with 5% CO 2 for 20 hrs and washed once before use in assays. 463
For time course experiments, infected CEM cells were incubated for 12, 18, 24, 36 and 48 hrs 464 post-spinoculation before use in assays. For some infection conditions, the fusion inhibitor 465 T20 (Roche) was added at 10µg/ml before or 4 hrs after spinoculation with HIV-1 AD8 . 466 were used. The GFP-reporter HIV-1 ADA was produced with the pNL4.3(ADA)-469 GFP.IRES.Nef plasmid containing intact or defective nef and vpu genes as previously 470 described (6, 9) . Similarly, the transmitted/founder HIV-1 infectious molecular clone 471 CH077.t (accession number JN944941) was produced using plasmids containing intact or 472 defective nef and vpu genes as previously described (36-39). CH077.t HIV-1 defective for 473
Nef and Vpu expression was generated by introducing two stop codons directly after the start 474 codon of nef and vpu (40). VSV-G pseudotyping was used to achieve similar levels of 475 infection between the wildtype and Nef-and Vpu-deleted viruses. This pseudotyping did not 476 affect HIV-1 Env expression or the recognition of infected cells by A32 or HIV-1 + sera (data 477 not shown). Prior to infection, primary CD4 + T cells were activated with 478 phytohemagglutinin-L (10µg/ml) for 48 hrs and maintained in RF20 media (RPMI-1640 479 media supplemented with 20% fetal bovine serum and 1% penicillin-streptomycin-L-480 glutamine) in the presence of recombinant IL-2 (100U/ml). The activated primary CD4 + T 481 cells were then infected with GFP-reporter HIV-1 ADA or CH077.t HIV-1 in 96-well plates by 482 spinoculation at 800g for 1 hr at 25ºC. HIV-1 ADA -infected cells were incubated for 48 hrs 483 while CH077.t HIV-1-infected cells were incubated for 18 hrs prior to use in assays. 484 485
Flow cytometric analysis of HIV-1-infected cells 486
CEM cells infected with GFP-reporter HIV-1 AD8 were incubated with HIV-1 + plasma 487 samples (1:1000 dilution) or Env-specific mAbs (5µg/ml) for 30 mins at room temperature. 488
To block CD4i epitopes, the infected cells were pre-incubated with A32 Fab at 10µg/ml for 489 15 mins at room temperature and washed prior to the addition of HIV-1 + plasma. The binding 490 of HIV-1 + plasma antibodies was then assessed with an APC-conjugated secondary mouse 491 anti-human IgG Fc antibody (1:200 dilution; clone HP6017, Biolegend), while the binding of 492 on March 18, 2019 by guest http://jvi.asm.org/
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Env-specific monoclonal antibodies was assessed with an AF647-conjugated secondary goat 493 anti-human IgG antibody (1:1000 dilution; Thermo Fisher Scientific). Cells were 494 concurrently stained with BV605-conjugated anti-CD4 antibody (clone OKT4, Biolegend) 495 for 30 mins at room temperature. For the detection of HIV-1 virions on the surface of "HIV-496 1-exposed" cells and intracellular HIV-1 p24 expression in infected cells, cells were fixed 497 with 1% formaldehyde and permeabilized with 1× fluorescence-activated cell sorting (FACS) 498 permeabilization buffer (BD) prior to staining with the PE-conjugated anti-p24 antibody 499
(1:1250 dilution; clone KC57, Beckman Coulter). Finally, cells were fixed with 1% 500 formaldehyde and acquired on the LSRFortessa flow cytometer (BD). 501 502 Primary CD4 + T cells infected with GFP-reporter HIV-1 ADA and the 503 transmitted/founder HIV-1 infectious molecular clone CH077.t were incubated with BV421-504 conjugated anti-CD4 antibody (clone OKT4, Biolegend) and HIV-1 + sera samples (1:1000 505 dilution) or Env-specific mAbs (5µg/ml) for 30 mins at room temperature. Cells were then 506 stained with AF647-conjugated goat anti-human secondary antibody (1µg/ml; Thermo Fisher 507 Scientific) for 15 mins at room temperature. Viability of the primary cells was determined via 508 staining with the AquaVivid viability dye (Thermo Fisher Scientific). Next, as a measure of 509 HIV-1 infection, cells infected with CH077.t were fixed and permeabilized with the 510 Cytofix/Cytoperm Fixation/Permeabilization Kit (BD) prior to intracellular staining for HIV-511 1 p24 using the PE-conjugated anti-p24 antibody (1:100 dilution; clone KC57, Beckman 512 Coulter). Lastly, both cells infected with GFP-reporter HIV-1 ADA and CH077.t were fixed 513 with 2% formaldehyde and acquired on the LSRII flow cytometer. For the experiments examining ADCC against "HIV-1-exposed cells", CEM cells 537 were pre-incubated with an anti-CD4 antibody that blocks gp120 binding (clone RPA-T4, 538
Biolegend) or a mouse isotype control (clone MOPC-21, Biolegend) at 20µg/ml for 30 mins 539 prior to spinoculation with HIV-1 AD8 at 1200g and 21ºC for 1 hr. After spinoculation, the 540 
